The latest report entitled Keeping Dementia Front of Mind highlights the prevalence of the brain condition for governments when making policy and budget decisions. Research has shown brainpower peaks in the mid-twenties and then declines and we lose up to 50% of our brain’s capacity by our mid-fifties. Quincy Bioscience is developing a new approach toward this growing problem.
Madison, Wis (Vocus) February 9, 2010 -- The latest report entitled “Keeping Dementia Front of Mind” highlights the prevalence of the brain condition for governments when making policy and budget decisions. Research has shown brainpower peaks in the mid-twenties and then declines and we lose up to 50% of our brain’s capacity by our mid-fifties. Quincy Bioscience is developing a new approach toward this growing problem.
There are 77 million Baby Boomers in the United States are rapidly growing. A discussion about dementia is uncomfortable, but will be impossible to avoid for many. “People are afraid of the unknown and scared of the memory loss they are seeing in aging relatives,” says Quincy Bioscience president Mark Underwood. “However, there is hope coming around the corner.”
Without a breakthrough in the fight against dementia, this number could jump to as many as 84 million who have age-related memory loss by the year 2040. Dementia is a subject avoided by most. Just the thought of memory loss - in a loved one, friend, co-worker or, worse yet, ourselves -- makes us terribly uncomfortable. Unless we are confronted directly with dementia, we prefer to think of it as "someone else's problem."
“Aging is scary and the solutions we have been researching can give people some peace. We now know why the brain loses its “horsepower” by age 55, and we have found a solution in nature to replace this key component.” Underwood continues, referring to his company’s discovery.
The hope lies within some technology developed at Quincy Bioscience, a biotechnology company headquartered in Madison, Wisconsin. They have developed a technology to help keep brain cells alive longer and hopefully to fight the ravages of dementia. “We have demonstrated keeping brain cells alive in animal tissues and these techniques crossover to help with the human mind also.” The key component was isolated in a jellyfish, a protein, a simple component that allows jellyfish to sting, but people not to be “stung” by the age-related changes that lead to dementia.
Underwood states, “Our population is "graying" and our citizens are living much longer than any previous generation. The fastest growing segment of our population is the over 80 age group, and the odds of becoming demented for the very elderly are much higher. So we have to act now, to protect our nation’s best and most precious resources, our brains.”
Quincy Bioscience (www.quincybioscience.com) is a biotechnology company based in Madison, Wisconsin. Quincy Bioscience is focused on the discovery, development and commercialization of novel compounds to fight the aging process. The company's products focus on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms. Quincy Bioscience is developing health applications of the jellyfish protein apoaequorin for dietary supplement and pharmaceutical products. The company’s first product, Prevagen (www.prevagen.com), was launched in the fall of 2007 and is intended to supplement the loss of critical calcium-binding proteins depleted in the normal course of healthy aging.
*These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
**Health and dementia statistics are from the Alzheimer's Association, the National Center for Health Statistics, the Center for Disease Control, and Alzheimer's Australia.
Read the full story at http://www.prweb.com/releases/2010/02/prweb3582244.htm.
Copyright©2010 Vocus, Inc.
All rights reserved